John Pasquini
Interventional Cardiology · Charlotte, NCNPI 1740288059
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,736 of the $32,302 with a category attached, or 92.1%. Amgen accounts for 95.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $11,601 and has fallen 92.5% since, to $868 in 2023.
Across 59 payments — averaging $547.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Amarin Pharma, Inc.$295
- Novartis$238
- Edwards Lifesciences$143
- Johnson & Johnson$124
- E.r. Squibb & Sons, L.L.C.$112
- plus $427 from 6 others
Across 220 payments — averaging $5624.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$549K
- Novartis$419K
- Kowa Research Institute, Inc.$111K
- Esperion Therapeutics, Inc.$91K
- AstraZeneca$38K
- Astrazeneca UK Limited$15K
- plus $14K from 4 others
What the payments were for
- Speaking & faculty fees$29,73692%
- Travel & lodging$2231%
- Food & beverage$2,3437%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $30,963 |
| Amarin Pharma, Inc. | 3 | $295 |
| Novartis | 8 | $238 |
| Edwards Lifesciences | 1 | $143 |
| Johnson & Johnson | 7 | $124 |
| E.r. Squibb & Sons, L.L.C. | 2 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $108 |
| Akcea Therapeutics, Inc. | 1 | $103 |
| Boston Scientific | 2 | $95 |
| EKOS Corporation | 1 | $92 |
| Heartflow, Inc. | 1 | $16 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$30,303
- Edwards SAPIEN 3 Transcatheter Heart Valve$143
- LEQVIO$117
- Vascepa$110
- DISEASE STATE$108
- TEGSEDI$103
- ELIQUIS$102
How this compares
$32,302 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $133,627 |
| Repatha SureclickEvolocumab | 182 | $133,313 |
| EntrestoSacubitril/Valsartan | 47 | $62,548 |
| XareltoRivaroxaban | 28 | $42,186 |
| JardianceEmpagliflozin | 11 | $12,858 |
| Praluent PenAlirocumab | 22 | $11,829 |
| FarxigaDapagliflozin Propanediol | 12 | $8,255 |
| Ezetimibe | 341 | $7,233 |
| Rosuvastatin Calcium | 294 | $3,905 |
| Atorvastatin Calcium | 207 | $2,555 |
| Pitavastatin Calcium | 15 | $2,261 |
| Metoprolol Succinate | 113 | $1,900 |
| Ranolazine ErRanolazine | 20 | $1,845 |
| Nitroglycerin | 19 | $1,351 |
| ClopidogrelClopidogrel Bisulfate | 70 | $1,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $238 | $62,54847 claims |
| Johnson & JohnsonXarelto | $124 | $42,18628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Charlotte
- Oluseun AlliCharlotte$485K
- Glen FandettiCharlotte$46K
- Aamer QureshiCharlotte$27K
- Daniel PuCharlotte$23K
- Nyal BorgesCharlotte$18K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.